Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
Por:
Alvarez-Lopez I, Bezares S, Portulas E, Garcia-Martinez E, Garcia-Saenz J, Gil-Gil M, de Duenas E, Ribelles N, Bertran A
Publicada:
1 ago 2020
Ahead of Print:
1 feb 2020
Resumen:
Purpose Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making. Methods This consensus document was generated using a modification of the RAND/UCLA methodology, which included the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 64 medical oncologists specializing in breast cancer. Results A Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic decision-making. Conclusion We have developed a consensus document with recommendations on the treatment of patients with HER2-negative luminal MBC that will help to improve therapeutic benefits.
Filiaciones:
Alvarez-Lopez I:
Hosp Univ Donostia BioDonostia, Begiristain Doktorea Pasealekua 109, Donostia San Sebastian 20014, Gipuzkoa, Spain
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Bezares S:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Portulas E:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Parc Tauli, Hosp Univ, Barcelona, Spain
Garcia-Martinez E:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Hosp Gen Univ Morales Meseguer, Murcia, Spain
Garcia-Saenz J:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Hosp Clin San Carlos, Madrid, Spain
CIBERONC ISCIII, Ctr Invest Biomed Red Oncol, Madrid, Spain
Gil-Gil M:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
ICO Bellvitge, Barcelona, Spain
de Duenas E:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain
Ribelles N:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Hosp Univ Reg & Virgen Victoria Malaga, Unidad Gest Clin Intercentros Oncol Med, Malaga, Spain
Inst Invest Biomed Malaga IBIMA CIMES UMA, Malaga 29010, Spain
Bertran A:
GEICAM Spanish Breast Canc Grp, Grp GEICAM Invest Canc Mama, Madrid, Spain
Hosp Univ & Politecn La Fe, Valencia, Spain
|